Benjamin Oakes, Scribe Therapeutics CEO

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

“CRISPR-by-de­sign” is the idea be­hind Scribe Ther­a­peu­tics, a com­pa­ny spun out from Jen­nifer Doud­na’s No­bel-win­ning lab that’s com­pet­ing in a close­ly-tracked field of genome ed­i­tor com­pa­nies just start­ing to make their way to the clin­ic.

Af­ter nab­bing $100 mil­lion last March for its Se­ries B fund­ing round, Scribe is tak­ing a dif­fer­ent tack from some of its com­peti­tors, craft­ing a new en­zyme iso­lat­ed from bac­te­ria called CasX, which has now been tweaked ex­ten­sive­ly and may be tar­get­ed to a range of genome-re­lat­ed dis­eases, of­fer­ing a pletho­ra of ther­a­peu­tic op­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.